221 related articles for article (PubMed ID: 24164966)
1. Identification of type II inhibitors targeting BRAF using privileged pharmacophores.
Zhang Q; Wang J; Wang F; Chen X; He Y; You Q; Zhou H
Chem Biol Drug Des; 2014 Jan; 83(1):27-36. PubMed ID: 24164966
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 1-(3,3-dimethylbutyl)-3-(2-fluoro-4-methyl-5-(7-methyl-2-(methylamino)pyrido[2,3-d]pyrimidin-6-yl)phenyl)urea (LY3009120) as a pan-RAF inhibitor with minimal paradoxical activation and activity against BRAF or RAS mutant tumor cells.
Henry JR; Kaufman MD; Peng SB; Ahn YM; Caldwell TM; Vogeti L; Telikepalli H; Lu WP; Hood MM; Rutkoski TJ; Smith BD; Vogeti S; Miller D; Wise SC; Chun L; Zhang X; Zhang Y; Kays L; Hipskind PA; Wrobleski AD; Lobb KL; Clay JM; Cohen JD; Walgren JL; McCann D; Patel P; Clawson DK; Guo S; Manglicmot D; Groshong C; Logan C; Starling JJ; Flynn DL
J Med Chem; 2015 May; 58(10):4165-79. PubMed ID: 25965804
[TBL] [Abstract][Full Text] [Related]
3. Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments.
Zhang Q; Zhang X; You Q
Molecules; 2016 Jul; 21(7):. PubMed ID: 27438814
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of benzyl 2-(1H-imidazole-1-yl) pyrimidine analogues as selective and potent Raf inhibitors.
Kim M; Lee J; Jung K; Kim H; Aman W; Ryu JS; Hah JM
Bioorg Med Chem Lett; 2014 Aug; 24(15):3600-4. PubMed ID: 24878193
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, biological evaluation of novel 4,5-dihydro-2H-pyrazole 2-hydroxyphenyl derivatives as BRAF inhibitors.
Liu JJ; Zhang H; Sun J; Wang ZC; Yang YS; Li DD; Zhang F; Gong HB; Zhu HL
Bioorg Med Chem; 2012 Oct; 20(20):6089-96. PubMed ID: 22985957
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
7. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
El-Nassan HB
Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
[TBL] [Abstract][Full Text] [Related]
8. Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E.
Rowbottom MW; Faraoni R; Chao Q; Campbell BT; Lai AG; Setti E; Ezawa M; Sprankle KG; Abraham S; Tran L; Struss B; Gibney M; Armstrong RC; Gunawardane RN; Nepomuceno RR; Valenta I; Hua H; Gardner MF; Cramer MD; Gitnick D; Insko DE; Apuy JL; Jones-Bolin S; Ghose AK; Herbertz T; Ator MA; Dorsey BD; Ruggeri B; Williams M; Bhagwat S; James J; Holladay MW
J Med Chem; 2012 Feb; 55(3):1082-105. PubMed ID: 22168626
[TBL] [Abstract][Full Text] [Related]
9. Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies.
Fu Y; Wang Y; Wan S; Li Z; Wang G; Zhang J; Wu X
Molecules; 2017 Mar; 22(4):. PubMed ID: 28353640
[TBL] [Abstract][Full Text] [Related]
10. 4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors.
Holladay MW; Campbell BT; Rowbottom MW; Chao Q; Sprankle KG; Lai AG; Abraham S; Setti E; Faraoni R; Tran L; Armstrong RC; Gunawardane RN; Gardner MF; Cramer MD; Gitnick D; Ator MA; Dorsey BD; Ruggeri BR; Williams M; Bhagwat SS; James J
Bioorg Med Chem Lett; 2011 Sep; 21(18):5342-6. PubMed ID: 21807507
[TBL] [Abstract][Full Text] [Related]
11. Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors.
Gopalsamy A; Ciszewski G; Hu Y; Lee F; Feldberg L; Frommer E; Kim S; Collins K; Wojciechowicz D; Mallon R
Bioorg Med Chem Lett; 2009 May; 19(10):2735-8. PubMed ID: 19362830
[TBL] [Abstract][Full Text] [Related]
12. AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Wang H; Quan H; Lou L
Biochem Biophys Res Commun; 2017 Jul; 489(1):14-20. PubMed ID: 28536078
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.
Chen SH; Zhang Y; Van Horn RD; Yin T; Buchanan S; Yadav V; Mochalkin I; Wong SS; Yue YG; Huber L; Conti I; Henry JR; Starling JJ; Plowman GD; Peng SB
Cancer Discov; 2016 Mar; 6(3):300-15. PubMed ID: 26732095
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and evaluation of novel diaryl urea derivatives as potential antitumor agents.
Lu C; Tang K; Li Y; Li P; Lin Z; Yin D; Chen X; Huang H
Eur J Med Chem; 2014 Apr; 77():351-60. PubMed ID: 24675135
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of novel 5-phenyl-1H-pyrazole derivatives as potential BRAF(V600E) inhibitors.
Wang SF; Zhu YL; Zhu PT; Makawana JA; Zhang YL; Zhao MY; Lv PC; Zhu HL
Bioorg Med Chem; 2014 Nov; 22(21):6201-8. PubMed ID: 25267006
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of bis-aryl ureas and amides based on 2-amino-3-purinylpyridine scaffold as DFG-out B-Raf kinase inhibitors.
Yang W; Chen Y; Zhou X; Gu Y; Qian W; Zhang F; Han W; Lu T; Tang W
Eur J Med Chem; 2015 Jan; 89():581-96. PubMed ID: 25462267
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, biological evaluation and molecular docking of novel 5-phenyl-1H-pyrazol derivatives as potential BRAF(V600E) inhibitors.
Dong JJ; Li QS; Wang SF; Li CY; Zhao X; Qiu HY; Zhao MY; Zhu HL
Org Biomol Chem; 2013 Oct; 11(37):6328-37. PubMed ID: 23942809
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
Peng SB; Henry JR; Kaufman MD; Lu WP; Smith BD; Vogeti S; Rutkoski TJ; Wise S; Chun L; Zhang Y; Van Horn RD; Yin T; Zhang X; Yadav V; Chen SH; Gong X; Ma X; Webster Y; Buchanan S; Mochalkin I; Huber L; Kays L; Donoho GP; Walgren J; McCann D; Patel P; Conti I; Plowman GD; Starling JJ; Flynn DL
Cancer Cell; 2015 Sep; 28(3):384-98. PubMed ID: 26343583
[TBL] [Abstract][Full Text] [Related]
19. Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic
Miyauchi S; Shien K; Takeda T; Araki K; Nakata K; Miura A; Takahashi Y; Kurihara E; Ogoshi Y; Namba K; Suzawa K; Yamamoto H; Okazaki M; Soh J; Tomida S; Yamane M; Sakaguchi M; Toyooka S
Anticancer Res; 2020 May; 40(5):2667-2673. PubMed ID: 32366411
[TBL] [Abstract][Full Text] [Related]
20. Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group.
Suijkerbuijk BM; Niculescu-Duvaz I; Gaulon C; Dijkstra HP; Niculescu-Duvaz D; Ménard D; Zambon A; Nourry A; Davies L; Manne HA; Friedlos F; Ogilvie LM; Hedley D; Lopes F; Preece NP; Moreno-Farre J; Raynaud FI; Kirk R; Whittaker S; Marais R; Springer CJ
J Med Chem; 2010 Apr; 53(7):2741-56. PubMed ID: 20199087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]